Global Biologic & Biosimilar RA Drugs Market Segments 2024, Forecast To 2033
5 Mar, 2024
The biologic & biosimilar RA drugs market has shown strong growth, increasing from $13.44 billion in 2023 to $14.15 billion in 2024, achieving a CAGR of 5.3%. Contributing factors include market adoption rates, clinical trial outcomes, market share changes, long-term patient outcomes, and pricing strategies. Expecting strong growth, the market is forecasted to reach $18.16 billion in 2028, maintaining a CAGR of 6.4%. Drivers encompass increasing biologic drug development, market competition, healthcare policies, patient preferences, and clinical research & development. Major trends include a rise in biosimilar market competition, personalized medicine and precision therapy, advancements in drug delivery systems, focus on safety and efficacy, and patient-centric healthcare.
Global Biologic & Biosimilar RA Drugs Market Key Driver
The biologics and biosimilar RA drugs market is growing with the rising older population and increasing incidence of rheumatoid arthritis. The global older population is expected to reach 2.1 billion by 2050, contributing to the growing demand for biologics and biosimilar RA drugs.
Get A Free Sample Of The Global Biologic & Biosimilar RA Drugs Market ReportGlobal Biologic & Biosimilar RA Drugs Market Segments
The biologic & biosimilar ra drugs market covered in this report is segmented –
1) By Source: Microbial, Mammalian, Other Sources
2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases
3) By Manufacturing: Outsourced, In-House
4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography: The regions covered in the anti inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the biologic & biosimilar RA drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Biologic & Biosimilar RA Drugs Industry Players
Samsung BioLogics Co. Ltd.; Amgen Inc.; Novo Nordisk A/S; AbbVie Inc.; Johnson & Johnson Services Inc.; Pfizer Inc.; Merck & Co. Inc.; Eli Lilly and Company; Novartis AG; Bayer AG; F. Hoffmann-La Roche Ltd.; AstraZeneca PLC.; Teva Pharmaceutical Industries Ltd.; Fresenius Se & Co. KGaA; Stada Arzneimittel AG; Boehringer Ingelheim Pharmaceuticals Inc.; Gedeon Richter Plc.; La Roche Ltd.; Regeneron Pharmaceuticals Inc.; Bristol-Myers Squibb Company; Dr. Reddy's Laboratories Ltd.; Biogen Inc.; Genentech Inc.; GlaxoSmithKline plc; Mylan N.V.; Sandoz International GmbH; Amneal Pharmaceuticals LLC; Apotex Inc.; Biocon Ltd.; Coherus BioSciences Inc.
Get The Full Global Biologic & Biosimilar RA Drugs Market Report
AIOps Biologic & Biosimilar RA Drugs Market Overview
Biologics and biosimilars refer to a class of drugs that are extracted from living organisms such as living cells, microorganisms, and other living creatures. Biosimilars are biologics that have similar characteristics to an already approved biological molecule. These drugs are used for the treatment of rheumatoid arthritis.
Biologic & Biosimilar RA Drugs Global Market Report 2023 provides data on the global biologic & biosimilar ra drugs market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The biologic & biosimilar ra drugs market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.